Staar Surgical Co: Form 10-Q for the period ended Apr 1, 2022
Filed with the SEC on May 4, 2022 and accepted by EDGAR at May 4, 2022, 16:14 ET.
Management's discussion and analysis
As filed, 16,430 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products; commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2022 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 23, 2022. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.
The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.
Overview
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.
Recent Developments
During the first quarter, ICL units grew 29% compared to the prior year quarter. Highlights included unit growth in China up 37%, Japan up 35% and India up 34%, all as compared to the prior year quarter. As previously announced in March, the FDA approved the EVO Visian ICL family of myopia lenses for sale in the U.S. Commercialization of EVO in the U.S. is underway in multiple cities. At this time, despite COVID-19 lockdowns in multiple cities in China, shipments of EVO lenses to China remain robust in anticipation of the upcoming summer implant season. Based on our global demand forecast, including projected release of remaining backlog lenses, we reaffirm our previously provided outlook for annual sales. For fiscal 2022 we continue to anticipate approximately $295 million in net sales, which represents year over year growth of 28%. We continue to monitor the commercial and operational impact of new variants of COVID-19 in our markets, which remains uncertain at this time and may adversely affect our financial results. We are also monitoring inflation globally, which may adversely affect our financial results in the future if it persists.
Critical Accounting Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.
Management believes that there have been no significant changes during the three months ended April 1, 2022 to the items that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Results of Operations
The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.
| Percentage of Net Sales for Three Months April 1, 2022 | April 2, 2021 | |
|---|---|---|
| Net sales | 100.0% | 100.0% |
| Cost of sales | 22.1% | 22.9% |
| Gross profit | 77.9% | 77.1% |
| General and administrative | 18.9% | 20.1% |
| Selling and marketing | 27.3% | 26.0% |
| Research and development | 12.6% | 16.3% |
| Total selling, general and administrative | 58.8% | 62.4% |
| Operating income | 19.1% | 14.7% |
| Total other expense, net | (0.9)% | (2.4)% |
| Income before income taxes | 18.2% | 12.3% |
| Provision for income taxes | 3.0% | 2.5% |
| Net income | 15.2% | 9.8% |
Net Sales
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| ICLs | $58,675 | $46,501 | 26.2% |
| Other product sales: | |||
| Cataract IOLs | 2,902 | 3,725 | (22.1)% |
| Other surgical products | 1,623 | 526 | —* |
| Total other product sales | 4,525 | 4,251 | 6.4% |
| Net sales | $63,200 | $50,752 | 24.5% |
* Denotes change is greater than +100%.
Net sales for the three months ended April 1, 2022 increased 25% from the same period of 2021. The increase in net sales was due to increased ICL sales of $12.2 million. Changes in foreign currency unfavorably impacted net sales by $1.9 million.
Total ICL sales for the three months ended April 1, 2022 increased 26% from the same period of 2021, with unit increase of 29%. The APAC region sales increased by 35%, with unit growth up 34%, due to sales growth in other APAC Distributors up 58%, China up 44%, India up 38%, Japan up 21% and Korea up 14%. The Europe, Middle East, Africa and Latin America region sales decreased 1% with unit increase of 6%, due to sales decreases in the Middle East and North
Africa down 16%, Germany down 14% and United Kingdom down 6%, offset by growth in Latin America up 45%, Distributor Operations up 5% and Spain up 4%. The North America region sales increased 20%, with unit increase of 17%, due to sales growth in Canada up 25% and the U.S. up 19%. Changes in foreign currency unfavorably impacted ICL sales by $1.4 million for the three months ended April 1, 2022. ICL sales represented 92.8% and 91.6% of our total sales for the three months ended April 1, 2022 and April 2, 2021, respectively.
Other product sales, including cataract IOLs for the three months ended April 1, 2022, increased 6% from the same period of 2021, due to increased preloaded injector part sales, partially offset by decreased sales of cataract IOLs. In the first half of 2021, we experienced product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers. Changes in foreign currency unfavorably impacted other product sales by $0.5 million for the three months April 1, 2022. Other product sales represented 7.2% and 8.4% of our total sales for the three months ended April 1, 2022 and April 2, 2021, respectively.
Gross Profit
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| Gross profit | $49,264 | $39,142 | 25.9% |
| Gross margin | 77.9% | 77.1% |
* Denotes change is greater than +100%.
Gross profit for the three months ended April 1, 2022 increased 25.9% from the same period of 2021. Gross profit margin increased to 77.9% of revenue for the three months ended April 1, 2022 compared to 77.1% of revenue for the three months ended April 2, 2021, due mainly to product and geographic sales mix and decreased period costs associated with manufacturing projects.
General and Administrative Expense
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| General and administrative expense | $11,940 | $10,212 | 16.9% |
| Percentage of sales | 18.9% | 20.1% |
General and administrative expenses for the three months ended April 1, 2022 increased 16.9% from the same period of 2021 due to increased facility costs, stock-based compensation expenses and salary-related and payroll tax expenses.
Selling and Marketing Expense
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| Selling and marketing expense | $17,270 | $13,201 | 30.8% |
| Percentage of sales | 27.3% | 26.0% |
Selling and marketing expenses for the three months ended April 1, 2022 increased 30.8% from the same period of 2021 due to increased advertising and promotional activities and salary-related and payroll tax expenses.
Research and Development Expense
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| Research and development expense | $7,941 | $8,259 | (3.9)% |
| Percentage of sales | 12.6% | 16.3% |
16
Research and development expenses for the three months ended April 1, 2022 decreased 3.9% from the same period of 2021 due mainly to decreased clinical expenses associated with our EVO clinical trial in the U.S.
Other Expense, Net
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| Other expense, net | $(586) | $(1,231) | 52.4% |
| Percentage of sales | (0.9)% | (2.4)% |
The change in other expense, net for the three months ended April 1, 2022 and April 2, 2021, was due primarily to decreased foreign exchange losses (primarily euro).
Income Taxes
| Three Months Ended April 1, 2022 | April 2, 2021 | Percentage Change 2022 vs. 2021 | |
|---|---|---|---|
| Income tax provision | $1,925 | $1,247 | 54.4% |
The effective tax rates for the three months ended April 1, 2022 and April 2, 2021 was 16.7% and 20.0%, respectively. Our effective tax rates differ from the U.S. federal statutory rate of 21% for the three months ended April 1, 2022 and April 2, 2021, respectively, primarily due to the income taxes generated in foreign jurisdictions. The effective tax rate for the first three months of 2022 was lower than the same period in 2021 primarily due to jurisdictions in which the income is earned.
Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly.
Liquidity and Capital Resources
We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Our financial condition at April 1, 2022 and December 31, 2021 included the following (in millions):
| April 1, 2022 | December 31, 2021 | 2022 vs. 2021 | |
|---|---|---|---|
| Cash and cash equivalents | $193.1 | $199.7 | $(6.6) |
| Current assets | $273.9 | $271.4 | $2.5 |
| Current liabilities | 41.2 | 48.8 | (7.6) |
| Working capital | $232.7 | $222.6 | $10.1 |
We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We do not have any off-balance sheet arrangements.
A summary of cash flows for the three months ended April 1, 2022 and April 2, 2021 was as follows (dollars in thousands):
| Cash flows from: | Three Months Ended April 1, 2022 | April 2, 2021 |
|---|---|---|
| Operating activities | $(4,610) | $6,766 |
| Investing activities | (2,539) | (2,159) |
| Financing activities | 894 | 6,000 |
| Effect of exchange rate changes | (384) | (716) |
| Net increase (decrease) in cash and cash equivalents | (6,639) | 9,891 |
| Cash and cash equivalents, at beginning of year | 199,706 | 152,453 |
| Cash and cash equivalents, at end of year | $193,067 | $162,344 |
For the three months ended April 1, 2022 net cash used by operating activities consisted of $19.3 million in working-capital changes, offset by $9.6 million in net income and $5.2 in non-cash items.
The increase in investments of property, plant and equipment for the three months ended April 1, 2022 relative to the same period of 2021, was due to increased investments in manufacturing facilities.
Net cash provided by financing activities for the three months ended April 1, 2022 consisted of $0.9 million of proceeds from the exercise of stock options. For the three months ended April 2, 2021, net cash provided by financing activities consisted of $6.2 million of proceeds from the exercise of stock options, partially offset by $0.2 million repayment of finance lease obligations.
Commitments
Employment Agreements
The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.
Market risk
As filed, 241 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
During the three months ended April 1, 2022, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Controls and procedures
As filed, 3,361 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended April 1, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 452 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 31, 2021. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-04-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-01-01 to 2022-04-01 | $63.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2022-01-01 to 2022-04-01 | $13.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-01-01 to 2022-04-01 | $49.3m | us-gaap:GrossProfit |
| Research and development | 3 months2022-01-01 to 2022-04-01 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-01-01 to 2022-04-01 | $37.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-01-01 to 2022-04-01 | $12.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-01-01 to 2022-04-01 | $1.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-04-01 | $9.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-01-01 to 2022-04-01 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-01-01 to 2022-04-01 | $0.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-01-01 to 2022-04-01 | 49,288,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-01-01 to 2022-04-01 | −$4.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-04-01 | $2.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-04-01 | $193.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-04-01 | $273.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-04-01 | $351.2m | us-gaap:Assets |
| Current liabilities | At period end2022-04-01 | $41.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-04-01 | $74.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-04-01 | $276.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-22-017859. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.